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A strict glycemic control reduces therisk of the development of micro-and macrovascular complications
(1–3). In the U.K. Prospective Diabetes
Study, each 1% reduction in HbA1c was
associated with a 37% decrease in risk for
microvascular complications and a 21%
decrease in risk for any end point or death
related to diabetes (3). In clinical practice,
a 3-monthly visit to the general practitio-
ner is recommended for the assessment of
glycemic control (4). There is now much
debate on the effectiveness of self-
monitoring of blood glucose (SMBG) as a
tool in the self-management of diabetic
patients (1,5,6).
SMBG aims at collecting information
on blood glucose levels at different time
points during the day and allows for the
timely identification of high levels. SMBG
has proven effective for patients with type
1 diabetes (7–9) and patients with type 2
diabetes who are using insulin (10–12)
because the information about a patient’s
glucose level is useful to refine and adjust
insulin dosages, resulting in an improved
glycemic control. It has been suggested
that patients with type 2 diabetes who are
not using insulin might also benefit from
SMBG (13). These patients might cope
more independently with their disease
when using SMBG, and they might
achieve a better understanding about the
factors that affect their disease and poten-
tially a better perceived quality of life.
SMBG might also improve adherence to
pharmacological treatment and motivate
patients to make appropriate lifestyle
changes (10,14).
Until 2001, several reviews investi-
gated the literature on the effectiveness of
SMBG in patients with type 2 diabetes
who are not using insulin and reported no
clear effects of SMBG on HbA1c (1,5,6,
15). Other outcome measures like quality
of life were not discussed. Moreover,
these reviews had some methodological
limitations, and some reviews also in-
cluded a study of insulin-using patients
with type 2 diabetes, while the content
and efficacy of self-management educa-
tion and also SMBG is expected to depend
on type of treatment (1,6,15). One review
only searched Medline, and criteria for
the methodological quality of the studies
and data extraction methods were not
clearly described (5). In another review, a
meta-analysis was performed, but hetero-
geneity and poor quality of the included
studies were reported (1,6).
The aim of our review was to assess
the effects of SMBG relative to usual care
without SMBG on glycemic control, qual-
ity of life and well-being, patient satisfac-
tion, and hypoglycemic episodes in
patients with type 2 diabetes who are not
using insulin.
RESEARCH DESIGN AND
METHODS
Identification of studies
This review was conducted within the
Metabolic and Endocrine Disorders Re-
view Group of the Cochrane Collaboration.
We identified relevant trials by searching
the Medline database of the National Li-
brary of Medicine (1966 to September
2004), The Cochrane Library (Issue 3,
2004), and EMBASE (1974 to September
2004). When searching both Medline and
EMBASE, 90% of the randomized con-
trolled trials available for the topic of the
review can be identified (16). Furthermore,
the Cochrane Central Register of Controlled
Trials (CENTRAL) includes citations to re-
ports of controlled trials that might not be
indexed in Medline or EMBASE (17). By
searching these three databases, we fulfilled
the requirements of the Cochrane Collabo-
ration, and we therefore consider our search
to be as valid as possible.
Search strategies were adapted from
the Cochrane Handbook (16,18) and The
Cochrane Metabolic and Endocrine Dis-
orders Review Group. The medical sub-
ject headings (MeSH) searched were
“randomized controlled trial” combined
with “diabetes mellitus, type II” and
“blood glucose self-monitoring,” includ-
ing all subheadings. Additionally, we
scanned the reference lists of the identi-
fied reviews and included studies for all
other relevant publications. We did not
search for unpublished trials, as this is
extremely time consuming and will prob-
ably lead to selection bias, as not all re-
searchers will answer. We did include
articles in press, found by notifications of
researchers in our network.
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Study selection
Two observers (L.M.C.W. and G.N.) in-
dependently inspected the titles and ab-
stracts of the identified references to
evaluate their potential eligibility. The full
article was retrieved for clarification if the
abstract did not provide enough informa-
tion or was not available. We included
studies investigating the effectiveness of
SMBG compared with usual care in pa-
tients with type 2 diabetes who were not
using insulin at baseline. Studies concern-
ing the comparison between SMBG and
urine glucose monitoring were also in-
cluded. We selected randomized con-
trolled trials only because these types of
study designs are considered to be more
valid in general and to give maximal
power for causal inference (19). Further-
more, the studies to be considered for in-
clusion in the review should have used at
least one of the following outcome mea-
sures: glycemic control measured by
HbA1c concentration and/or fasting
plasma glucose level, hypoglycemic epi-
sodes, quality of life (e.g., with the SF-36
[36-item short-form health survey] [20]),
well-being (e.g., by means of the well-
being questionnaire [21]), and/or patient
satisfaction (e.g., by means of the Diabetes
Treatment Satisfaction Questionnaire
[22]). No language restriction was ap-
plied. Studies were eliminated if both re-
viewers agreed that the study did not meet
the criteria for including studies in the
review. If necessary, a third party resolved
differences in opinion ( J.M.D.).
Methodological quality assessment
The methodological quality of the rele-
vant trials was assessed independently by
two reviewers (L.M.C.W. and E.B.) by
means of a score list. We used the Maas-
tricht-Amsterdam score list (23) for ran-
domized trials, which includes all criteria
of the lists by Jadad et al. (24) and Verha-
gen et al. (25). The original list consisted of
19 items. Commensurate with the recom-
mendation of Van Tulder et al. (23), we
only applied the 11 items pertaining to in-
ternal validity. Each item has a rating scale
of “yes” if bias was unlikely, “no” if bias was
likely, or “don’t know” if information con-
cerning the item was not available. Studies
fulfilling 6 of the 11 quality criteria
(50%) were considered to be of “high
quality.” All studies scoring less than six cri-
teria were rated as “low quality.”
The initial level of agreement between
the two reviewers (L.M.C.W. and E.B.)
was reported as Cohen’s  (26). Item-
level discrepancies were discussed, and if
consensus could not be reached, a third
reviewer (G.N.) made the final decision.
A pilot test, using two trials excluded
from the review, preceded the quality as-
sessment of the randomized controlled
trials in order to assess the feasibility of
using this scale. All items were clearly de-
fined, and both authors could obtain con-
sensus on each item in the list.
Data extraction
Data extraction from eligible trials was
performed using the items from the Co-
chrane Metabolic and Endocrine Disor-
ders Editorial base generic data extraction
form that were considered relevant by two
reviewers (L.M.C.W. and E.B.). The
adapted data extraction form included in-
formation about the authors, randomiza-
tion procedure, analyses, patients’
characteristics, type of intervention(s),
characteristics of methodological quality,
and results. Two reviewers (L.M.C.W.
and E.B.) independently performed data
extraction and data entry. Any discrepan-
cies between reviewers were resolved by
discussion, and if consensus could not be
reached, a third reviewer (G.N.) made the
final decision.
A pilot test, based on the same two
trials excluded from the review, preceded
the data extraction of the selected ran-
domized controlled trials in order to iden-
tify data that were not needed or missing.
The test was performed to optimize the
data extraction sheet and to obtain con-
sensus between reviewers about the form.
Data analysis
We performed a meta-analysis with the
HbA1c values of all studies, which was the
only outcome measure that was available
in all studies. We did separate analysis of
the two possible comparisons, SMBG ver-
sus usual care and SMBG versus self-
monitoring of urine glucose (SMUG). The
results of each study were plotted as point
estimates with corresponding 95% CIs. The
measures of effect for HbA1c were the differ-
ences from baseline to end point in both
groups. When the SDs for these differences
were missing, they were estimated with the
following formula. We used a conservative
correlation coefficient of 0.4 (27).
SDpaired difference  (SDbaseline)
2  (SDfinal)
2
 (2  r  SDbaseline  SDfinal)
Statistical heterogeneity was assessed by
visual inspection of the CIs in the forest
plot. Additionally, it was tested using the
Z score and the 2 statistic, with signifi-
cance set at P 	 0.10. Quantification of
the effect of heterogeneity was assessed by
means of I2, ranging from 0 to 100% and
including its 95% CI. I2 demonstrates the
percentage of total variation across stud-
ies due to heterogeneity and was used to
judge the consistency of evidence. The ev-
idence of statistical heterogeneity was
considered substantial if I2 was 50%
(28).
Clinical heterogeneity was assessed
by comparing the data extraction forms of
the studies. If studies are clinically homo-
geneous regarding study populations,
interventions, and outcomes, a meta-
analysis should use the fixed-effect
model. However, since clinical heteroge-
neity was observed, it was unlikely that
there was one “true” effect underlying the
data, and thus a random-effects model
was used.
The analyses were carried out by us-
ing the statistical module MetaView 4.2 in
Review Manager 4.2 (Cochrane Collabo-
ration, Oxford, U.K.).
RESULTS— The search of the com-
puterized databases identified a total of
572 citations. After excluding titles clearly
not related to the objective of our review,
97 studies were considered in the selec-
tion procedure. Screening of references
resulted in another 15 citations. After
reading the abstracts of the studies, if
available, 36 full-text articles were re-
trieved for further examination. Only five
eligible randomized controlled trials met
all inclusion criteria and were included in
this review (14,29–32). During the re-
view process, we received the notification
of an article in press that we also included
in our review (33).
Four studies compared SMBG with
usual care without monitoring (29,31–
33), one study compared SMBG with
urine glucose monitoring (30), and one
study was a three-armed trial comparing
all three interventions (14). Characteris-
tics and results of the included trials are
described in Table 1.
Methodological quality of included
studies
Initial agreement between both reviewers
on the overall methodological quality was
91%, and after the consensus meeting, no
Welschen and Associates
DIABETES CARE, VOLUME 28, NUMBER 6, JUNE 2005 1511
T
ab
le
1—
C
ha
ra
ct
er
is
ti
cs
of
ra
nd
om
iz
ed
co
nt
ro
ll
ed
tr
ia
ls
on
th
e
ef
fe
ct
iv
en
es
s
of
SM
B
G
in
pa
ti
en
ts
w
it
h
ty
pe
2
di
ab
et
es
w
ho
ar
e
no
t
us
in
g
in
su
li
n
St
ud
y
In
te
rv
en
ti
on
Pa
ti
en
ts
(n
)
D
ur
at
io
n
of
st
ud
y
Ba
se
lin
e
ch
ar
ac
te
ri
st
ic
s
(m
ea
n


SD
)
O
ut
co
m
es
(m
ea
n


SD
)
C
ha
ng
es
be
tw
ee
n
ba
se
lin
e
an
d
ou
tc
om
es
(m
ea
n


SD
)
C
om
m
en
ts
Fo
nt
bo
nn
e
(1
4)
,
19
89
,F
ra
nc
e
SM
BG
:m
ea
su
re
m
en
ts
tw
ic
e
ev
er
y
ot
he
r
da
y.
SM
U
G
:m
ea
su
re
m
en
ts
tw
ic
e
ev
er
y
ot
he
r
da
y.
C
on
tr
ol
:r
eg
ul
ar
H
bA
1c
de
te
rm
in
at
io
ns
ev
er
y
2
m
on
th
s
at
ph
ys
ic
ia
n,
no
se
lf-
m
on
it
or
in
g
SM
BG
68
,
SM
U
G
72
,
co
nt
ro
l6
8
6
m
on
th
s
SM
BG
:H
bA
1
c
8.
2


2.
5%
,
BM
I
27
.1


4.
1
kg
/m
2
,
ag
e
54
.5


10
.7
ye
ar
s,
di
ab
et
es
du
ra
ti
on
12
.2


6.
6
ye
ar
s;
SM
U
G
:
H
bA
1c
8.
6


2.
5%
,B
M
I
26
.0


3.
4
kg
/m
2
,a
ge
54
.9


10
.2
ye
ar
s,
di
ab
et
es
du
ra
ti
on
13
.3


6.
8
ye
ar
s;
co
nt
ro
l:
H
bA
1c
8.
2


2.
5%
,B
M
I
27
.0


4.
1
kg
/m
2
,a
ge
56
.3


9.
1
ye
ar
s,
di
ab
et
es
du
ra
ti
on
12
.7


0.
8
ye
ar
s
SM
BG
:H
bA
1
c
7.
84
%
;
SM
U
G
:H
bA
1
c
8.
47
%
;c
on
tr
ol
:
H
bA
1c
7.
7%
SM
BG
:H
bA
1
c

0.
36


3.
14
%
;
SM
U
G
:H
bA
1
c

0.
13


2.
20
%
;
co
nt
ro
l:
H
bA
1
c

0.
5


1.
54
%
W
it
hd
ra
w
al
s:
44
pa
ti
en
ts
(2
1%
)
lo
st
to
fo
llo
w
-u
p
(S
M
BG
12
,S
M
U
G
18
,c
on
tr
ol
14
).
C
om
pl
ia
nc
e:
ex
pe
ct
ed
nu
m
be
r
to
be
us
ed

18
2
(S
M
BG
91
st
ri
ps
,
SM
U
G
79
st
ri
ps
,P
	
0.
01
,p
oo
r
co
m
pl
ia
nc
e)
A
lle
n
(3
0)
,1
99
0,
U
.S
.
SM
BG
:a
tl
ea
st
36
bl
oo
d
gl
uc
os
e
de
te
rm
in
at
io
ns
/
m
on
th
,b
ef
or
e
ea
ch
m
ea
le
ve
ry
ot
he
r
da
y.
SM
U
G
:a
tl
ea
st
36
ur
in
e
gl
uc
os
e
de
te
rm
in
at
io
ns
/m
on
th
,
be
fo
re
ea
ch
m
ea
le
ve
ry
ot
he
r
da
y.
Bo
th
gr
ou
ps
:
st
an
da
rd
iz
ed
tr
ea
tm
en
t
pr
og
ra
m
in
cl
ud
in
g
di
et
an
d
ex
er
ci
se
co
un
se
lin
g.
U
se
of
an
al
go
ri
th
m
fo
r
tr
ea
tm
en
t
al
te
ra
tio
ns
by
ph
ys
ic
ia
n
SM
BG
27
,
SM
U
G
27
6
m
on
th
s
SM
BG
:H
bA
1
c
12
.4


3.
3%
,
FP
G
12
.0


2.
4
m
m
ol
/l,
ag
e
58
.2


9.
7
ye
ar
s,
di
ab
et
es
du
ra
ti
on
6.
8


6.
5
ye
ar
s;
SM
U
G
,
H
bA
1c
11
.7


3.
0%
,F
PG
12
.0


2.
6
m
m
ol
/l,
ag
e
57
.9


10
.7
ye
ar
s,
di
ab
et
es
du
ra
ti
on
9.
0


10
.3
ye
ar
s
SM
BG
:H
bA
1
c
10
.4


2.
9%
,F
PG
10
.6


3.
6
m
m
ol
/
l;
SM
U
G
:H
bA
1
c
9.
7


2.
6%
,F
PG
10
.5


3.
0
m
m
ol
/l
SM
BG
:H
bA
1
c

2.
0


3.
4%
,F
PG

1.
4


3.
2
m
m
ol
/l;
SM
U
G
:H
bA
1
c

2.
0


2.
4%
,F
PG

1.
5


2.
8
m
m
ol
/l
W
it
hd
ra
w
al
s:
7
pa
ti
en
ts
.
C
om
pl
ia
nc
e:
re
co
rd
s
co
m
pl
et
e
in
87
%
of
vi
si
ts
fo
r
SM
BG
an
d
in
90
%
of
vi
si
ts
fo
r
SM
U
G
.
A
tt
en
da
nc
e
at
m
on
th
ly
vi
si
ts
:
98
%
in
bo
th
gr
ou
ps
M
uc
hm
or
e
(2
9)
,
19
94
,U
.S
.
SM
BG
:i
nd
iv
id
ua
la
nd
gr
ou
p
te
ac
hi
ng
on
ca
rb
oh
yd
ra
te
co
un
tin
g
an
d
SM
BG
,m
ea
su
re
d
si
x
tim
es
da
ily
fo
r
4
w
ee
ks
.R
ed
uc
e
to
pr
e-
an
d
po
st
pr
an
di
al
te
st
in
g
of
a
si
ng
le
m
ea
l
pe
r
da
y
fo
r
w
ee
ks
4–
20
.B
ey
on
d
w
ee
k
20
,
in
di
vi
du
al
’s
el
ec
tio
n.
C
on
tr
ol
:i
de
nt
ic
al
am
ou
nt
of
at
te
nt
io
n,
fo
cu
s
on
ge
ne
ra
l
pr
in
ci
pl
es
of
di
ab
et
es
nu
tr
iti
on
SM
BG
12
,
co
nt
ro
l1
1
28
w
ee
ks
an
d
fo
llo
w
-u
p
un
ti
l
44
w
ee
ks
SM
BG
:H
bA
1
c
10
.2
9


1.
1%
,
BM
I3
5.
1


4.
8
kg
/m
2
,a
ge
57
.3


8.
0
ye
ar
s,
di
ab
et
es
du
ra
tio
n
5.
7


4.
8
ye
ar
s,
qu
al
ity
of
lif
e*
sa
tis
fa
ct
io
n
3.
1,
im
pa
ct
4,
w
or
ry
-
di
ab
et
es
re
la
te
d
4,
w
or
ry
-
so
ci
al
/v
oc
at
io
na
lr
el
at
ed
4.
6;
co
nt
ro
l:
H
bA
1
c
10
.4
5


1.
5%
,B
M
I
33
.3


4.
3
kg
/m
2
,a
ge
60
.1


7.
3
ye
ar
s,
di
ab
et
es
du
ra
tio
n
5.
2


4.
6
ye
ar
s,
qu
al
ity
of
lif
e*
sa
tis
fa
ct
io
n
3,
im
pa
ct
3.
9,
w
or
ry
-
di
ab
et
es
re
la
te
d
4.
1,
w
or
ry
-s
oc
ia
l/v
oc
at
io
na
l
re
la
te
d
4.
3
SM
BG
:H
bA
1
c
8.
75


1.
66
%
,
qu
al
it
y
of
lif
e*
sa
ti
sf
ac
ti
on
2.
7,
im
pa
ct
4.
1,
w
or
ry
-
di
ab
et
es
re
la
te
d
4.
6,
w
or
ry
-s
oc
ia
l/
vo
ca
ti
on
al
re
la
te
d
4.
6;
co
nt
ro
l:
H
bA
1
c
9.
6


2.
09
%
,
qu
al
it
y
of
lif
e*
sa
ti
sf
ac
ti
on
2.
7,
im
pa
ct
3.
9,
w
or
ry
-
di
ab
et
es
re
la
te
d
4.
5,
w
or
ry
-s
oc
ia
l/
vo
ca
ti
on
al
re
la
te
d
4.
6
SM
BG
:H
bA
1
c

1.
54


1.
46
%
,
qu
al
it
y
of
lif
e
sa
ti
sf
ac
ti
on

0.
4,
im
pa
ct

0.
1,
w
or
ry
-
di
ab
et
es
re
la
te
d

0.
6,
w
or
ry
-s
oc
ia
l/
vo
ca
ti
on
al
re
la
te
d


0;
co
nt
ro
l:
H
bA
1
c

0.
85


1.
87
%
,
qu
al
it
y
of
lif
e
sa
ti
sf
ac
ti
on

0.
3,
im
pa
ct


0,
w
or
ry
-
di
ab
et
es
re
la
te
d

0.
4,
w
or
ry
-s
oc
ia
l/v
oc
at
io
na
l
re
la
te
d

0.
3
W
it
hd
ra
w
al
s:
6
pa
ti
en
ts
of
29
re
cr
ui
te
d
dr
op
pe
d
ou
t
pr
io
r
to
or
at
th
e
ti
m
e
of
ra
nd
om
iz
at
io
n.
C
om
pl
ia
nc
e:
da
ta
as
ce
rt
ai
nm
en
t
fo
r
H
bA
1
c
w
as
96
%
co
m
pl
et
e.
O
ne
co
nt
ro
lg
ro
up
in
di
vi
du
al
di
d
no
t
co
m
pl
et
e
gr
ou
p
m
ee
ti
ng
s.
H
ig
h
co
m
pl
ia
nc
e
w
it
h
ca
rb
oh
yd
ra
te
co
un
ti
ng
.A
ve
ra
ge
pe
rf
or
m
an
ce
of
te
st
in
g
bl
oo
d
gl
uc
os
e
(4
.6
7
ti
m
es
pe
r
w
ee
k)
SMBG in non–insulin-using diabetic patients
1512 DIABETES CARE, VOLUME 28, NUMBER 6, JUNE 2005
Sc
hw
ed
es
(3
1)
,
20
02
,
m
ul
ti
ce
nt
er
st
ud
y
in
G
er
m
an
y
an
d
A
us
tr
ia
SM
BG
:m
ea
su
re
m
en
ts
of
bl
oo
d
gl
uc
os
e
si
x
tim
es
on
2
da
ys
pe
rw
ee
k
an
d
re
co
rd
in
gs
of
va
lu
es
ob
ta
in
ed
in
a
di
ar
y
fo
r
bl
oo
d
gl
uc
os
e
da
ta
an
d
do
cu
m
en
ta
tio
n
of
ea
tin
g
ha
bi
ts
an
d
st
at
e
of
w
el
l-
be
in
g.
Pa
tie
nt
s
w
er
e
se
en
ev
er
y
4
w
ee
ks
fo
r
co
un
se
lin
g
on
us
e
of
th
e
m
et
er
an
d
re
ga
rd
in
g
di
et
an
d
lif
es
ty
le
.C
on
tin
ua
l
us
e
of
th
e
gl
uc
os
e
m
et
er
du
rin
g
th
e
fo
llo
w
-u
p
pe
rio
d.
C
on
tr
ol
:n
on
st
an
-
da
rd
iz
ed
co
un
se
lin
g
w
ith
a
fo
cu
s
on
di
et
an
d
lif
es
ty
le
SM
BG
11
3,
co
nt
ro
l1
10
6
m
on
th
s
an
d
6
m
on
th
s
of
fo
llo
w
-u
p
SM
BG
:H
bA
1
c
8.
47


0.
86
%
,
BM
I3
1.
0


4.
6
kg
/m
2
,a
ge
58
.7


7.
6
ye
ar
s,
di
ab
et
es
du
ra
tio
n
5.
5


4.
8
ye
ar
s,
qu
al
ity
of
lif
e†
ge
ne
ra
lw
el
l-
be
in
g
26
.4


5.
4,
sa
tis
fa
ct
io
n
27
.6


7.
1;
co
nt
ro
l:
H
bA
1
c
8.
35


0.
75
%
,B
M
I
31
.9


5.
5
kg
/m
2
,a
ge
60
.5


6.
6
ye
ar
s,
di
ab
et
es
du
ra
tio
n
5.
2


3.
9
ye
ar
s,
qu
al
ity
of
lif
e†
ge
ne
ra
lw
el
l-
be
in
g
26
.5


5.
9,
sa
tis
fa
ct
io
n
27
.0


6.
6
SM
BG
:H
bA
1
c
7.
47


1.
27
%
,
qu
al
ity
of
lif
e†
ge
ne
ra
lw
el
l-
be
in
g
30
.4
,s
at
is
fa
ct
io
n
31
.1
2;
co
nt
ro
l:
H
bA
1
c
7.
81


1.
52
%
,q
ua
lit
y
of
lif
e†
ge
ne
ra
lw
el
l-
be
in
g
28
.5
,
sa
tis
fa
ct
io
n
30
.6
SM
BG
:H
bA
1
c

1.
0


1.
08
%
‡,
qu
al
it
y
of
lif
e
ge
ne
ra
l
w
el
l-
be
in
g

4.
0,
sa
ti
sf
ac
ti
on

3.
52
;
co
nt
ro
l:
H
bA
1
c

0.
54


1.
41
%
,
qu
al
it
y
of
lif
e
ge
ne
ra
l
w
el
l-
be
in
g

2.
0,
sa
ti
sf
ac
ti
on

3.
6
W
ith
dr
aw
al
s:
27
pa
tie
nt
s.
C
om
-
pl
ia
nc
e:
av
er
ag
e
nu
m
be
r
of
w
ee
kl
y
m
ea
su
re
m
en
ts
24
.8


3.
9
pe
r
pa
tie
nt
.B
lo
od
gl
uc
os
e/
ea
tin
g
di
ar
y
re
gu
la
rl
y
us
ed
by
97
.9
%
of
th
e
pa
tie
nt
s.
D
ur
in
g
fo
llo
w
-u
p,
87
%
of
th
e
pa
tie
nt
s
co
nt
in
ue
d
se
lf-
m
on
ito
ri
ng
G
ue
rc
i(
32
),
20
03
,F
ra
nc
e
SM
BG
:S
M
BG
in
ad
di
tio
n
to
th
e
co
nv
en
tio
na
l
la
bo
ra
to
ry
w
or
k-
up
.
Ed
uc
at
io
n
on
w
ei
gh
tl
os
s
an
d
ph
ys
ic
al
ac
tiv
ity
;
tr
ea
tm
en
ta
lte
ra
tio
ns
by
ph
ys
ic
ia
n.
M
ea
su
re
m
en
ts
at
le
as
ts
ix
tim
es
pe
rw
ee
k,
on
3
di
ffe
re
nt
da
ys
,
in
cl
ud
in
g
w
ee
ke
nd
s.
C
on
tr
ol
:c
on
ve
nt
io
na
l
la
bo
ra
to
ry
w
or
k-
up
ba
se
d
so
le
ly
on
la
bo
ra
to
ry
m
ea
su
re
m
en
to
fH
bA
1
c
ev
er
y
12
w
ee
ks
.
Ed
uc
at
io
n
on
w
ei
gh
tl
os
s
an
d
ph
ys
ic
al
ac
tiv
ity
;
tr
ea
tm
en
ta
lte
ra
tio
ns
by
ph
ys
ic
ia
n
SM
BG
34
5,
co
nt
ro
l3
44
24
w
ee
ks
SM
BG
:H
bA
1
c
9.
0


1.
3%
,
FP
G
7.
2


5.
1
m
m
ol
/l,
BM
I
30
.4


6.
1
kg
/m
2
,a
ge
60
.9


9.
4
ye
ar
s,
di
ab
et
es
du
ra
tio
n
7.
7


6.
3
ye
ar
s;
co
nt
ro
l:
H
bA
1
c
8.
9


1.
3%
,
FP
G
7.
5


4.
8
m
m
ol
/l,
BM
I
29
.7


4.
8
kg
/m
2
,a
ge
62
.2


9.
1
ye
ar
s,
di
ab
et
es
du
ra
tio
n
8.
4


6.
6
ye
ar
s
SM
BG
:H
bA
1
c
8.
1


1.
6%
,F
PG
6.
66


4.
8
m
m
ol
/l,
hy
po
gl
yc
em
ia
53
ep
is
od
es
‡;
co
nt
ro
l:
H
bA
1
c
8.
4


1.
4%
,
FP
G
6.
9


4.
6
m
m
ol
/l,
hy
po
-
gl
yc
em
ia
25
ep
is
od
es
SM
BG
:H
bA
1
c

0.
9


1.
54
%
‡,
FP
G

0.
54
m
m
ol
/l;
co
nt
ro
l:
H
bA
1
c

0.
5


1.
54
%
,F
PG

0.
6
m
m
ol
/l
D
ro
po
ut
s:
SM
BG
16
4
pa
tie
nt
s
(4
8%
),
co
nt
ro
l1
39
pa
tie
nt
s
(4
0%
).
C
om
pl
ia
nc
e:
no
tc
le
ar
D
av
id
so
n
(3
3)
,i
n
pr
es
s,
U
.S
.
SM
BG
:b
ef
or
e
an
d
be
tw
ee
n
1
an
d
2
h
af
te
re
at
in
g
m
ea
ls
6
da
ys
a
w
ee
k;
tw
o
br
ea
kf
as
ts
,t
w
o
lu
nc
he
s,
an
d
tw
o
su
pp
er
s.
Re
co
rd
in
gs
of
w
ha
tw
as
ea
te
n.
C
on
tr
ol
:r
eg
ul
ar
H
bA
1
c
de
te
rm
in
at
io
ns
ev
er
y
2
m
on
th
s
at
ph
ys
ic
ia
n,
no
se
lf-
m
on
i-
to
rin
g.
Bo
th
gr
ou
ps
:fi
ve
vi
si
ts
to
di
et
ic
ia
n
fo
re
du
-
ca
tio
n
on
nu
tr
iti
on
.
Su
pp
or
tb
y
nu
rs
e,
un
a-
w
ar
e
of
SM
BG
st
at
us
,a
c-
co
rd
in
g
to
de
ta
ile
d
al
go
rit
hm
s
to
m
ak
e
th
er
ap
eu
tic
de
ci
si
on
s
SM
BG
43
,
co
nt
ro
l4
5
6
m
on
th
s
SM
BG
:H
bA
1
c
8.
38


2.
12
%
,
BM
I3
1.
7


6.
7
kg
/m
2
,a
ge
49
.8


11
.2
ye
ar
s,
di
ab
et
es
du
ra
tio
n
5.
5


4.
7
ye
ar
s;
co
nt
ro
l:
H
bA
1
c
8.
5


2.
2%
,
BM
I3
3.
4


7.
0
kg
/m
2
,a
ge
50
.9


11
.0
ye
ar
s,
di
ab
et
es
du
ra
tio
n
5.
8


5.
8
ye
ar
s
SM
BG
:H
bA
1
c
7.
53


1.
55
%
;
co
nt
ro
l:
H
bA
1
c
7.
88


1.
5%
SM
BG
:H
bA
1
c

0.
8


1.
6%
;
co
nt
ro
l:
H
bA
1
c

0.
6


2.
1%
C
om
pl
ia
nc
e:
di
et
ar
y
vi
si
ts
:S
M
BG
4.
0


1.
0,
co
nt
ro
l
3.
2


0.
9.
SM
BG
av
er
ag
ed
12
9
of
28
8
re
ad
in
gs
(4
5%
)
*Q
ua
lit
y
of
lif
e
m
ea
su
re
d
by
th
e
di
ab
et
es
qu
al
it
y-
of
-l
ife
in
ve
nt
or
y
us
ed
by
th
e
D
ia
be
te
s
C
on
tr
ol
an
d
C
om
pl
ic
at
io
ns
T
ri
al
w
it
h
a
ra
ng
e
of
0
(w
or
st
)
to
5
(b
es
ts
co
re
)
(4
5)
.†
Q
ua
lit
y
of
lif
e
m
ea
su
re
d
by
th
e
Pa
ti
en
t
W
el
l-
be
in
g
Q
ue
st
io
nn
ai
re
,w
hi
ch
ha
s
a
fo
ur
-i
te
m
sc
al
e
w
it
h
a
ra
ng
e
of
0
(w
or
st
sc
or
e)
to
36
(b
es
t
sc
or
e)
(2
1)
,a
nd
th
e
D
ia
be
te
s
T
re
at
m
en
t
Sa
ti
sf
ac
ti
on
Q
ue
st
io
nn
ai
re
,w
hi
ch
ha
s
a
si
x-
it
em
sc
al
e
w
it
h
a
ra
ng
e
fr
om
0
(v
er
y
di
ss
at
is
fie
d)
to
36
(v
er
y
sa
ti
sfi
ed
)
(2
2)
.‡
St
at
is
ti
ca
lly
si
gn
ifi
ca
nt
di
ff
er
en
ce
be
tw
ee
n
gr
ou
ps
(P
	
0.
05
).
FP
G
,f
as
ti
ng
pl
as
m
a
gl
uc
os
e.
Welschen and Associates
DIABETES CARE, VOLUME 28, NUMBER 6, JUNE 2005 1513
disagreement persisted. The results of the
methodological quality assessment are
presented in Table 2. The studies of Allen
et al. (30) and Davidson et al. (33) were
considered to be of high quality by scor-
ing positive for 6 and 7 out of 11 criteria,
respectively. The studies of Schwedes et
al. (31), Fontbonne et al. (14), Muchmore
et al. (29), and Guerci et al. (32) scored
positive for five criteria, a level we consid-
ered to be of low quality.
With respect to cointerventions, such
as treatment with other medications or di-
etary advice, Allen et al. (30) and Guerci
et al. (32) reported that these were
avoided. Davidson et al. (33) provided the
same information in both groups. We
considered that the SMBG group in
Schwedes et al. (31) did receive a cointer-
vention by means of a structured counsel-
ing program every 4 weeks during the
intervention period, whereas the control
group received only a nonstandardized
counseling. Furthermore, Muchmore et
al. (29) provided individual and group
teaching on the concept of carbohydrate
counting for the intervention patients.
However, because the control group re-
ceived an identical amount of attention,
although with a focus on the general prin-
ciples of diabetes nutrition according to
ADA practice guidelines, we did not con-
sider a cointervention to have occurred in
this study. This consideration was based
on findings that more intention by care
providers is associated with an improve-
ment in HbA1c levels (34). Fontbonne et
al. (14) did not provide information on
this item. Five studies (14,29–31,33) had
an acceptable withdrawal/drop-out rate.
Guerci et al. (32) reported a drop-out rate
of 40%, which was considered nonac-
ceptable. The item on concealment of
treatment allocation was unclear or not
done in all studies.
Outcomes
HbA1c. In the meta-analysis, the overall
effect was a statistically significant de-
crease of 0.39% in HbA1c (95% CI0.56
to 0.21) in favor of SMBG compared
with the control group. The comparison
between SMBG and SMUG showed a non-
significant decrease of 0.17% (0.96 to
0.61) in HbA1c in favor of SMBG. There
was no statistical heterogeneity, as indi-
cated by visual inspection of the CIs, 2
statistic, or I2, which was 0%. However,
we found clinical heterogeneity between
the studies because of differences in base-
line data of the patients and type of inter-
ventions. Schwedes et al. (31) provided
education in the SMBG group only, which
we considered to be a cointervention. Re-
sults of the meta-analyses are shown in
Fig. 1.
Fasting plasma glucose. Only two stud-
ies measured fasting plasma glucose lev-
els. Both found a decrease as a result of
SMBG, though not statistically significant
(30,32).
Hypoglycemic episodes. Only Guerci
et al. (32) investigated the effect of SMBG
on the frequency of asymptomatic and
symptomatic (capillary blood glucose	3
mmol/l) hypoglycemia. They found a sig-
nificant difference in the number of pa-
tients who reported at least one episode of
asymptomatic hypoglycemia during the
study. We consider this to be an invalid
result because it was not possible for the
control group to measure this type of hy-
poglycemia. No serious episode of hypo-
glycemia was reported during this study.
Quality of life, well-being, and patient
satisfaction. Muchmore et al. (29)
found identical results in the SMBG and
control group for the improvement in
quality of life scales (satisfaction, impact,
worry-social/vocational, and worry-
diabetes related). Schwedes et al. (31) also
found that well-being and treatment sat-
isfaction improved to the same extent in
both groups. Neither study found any sta-
tistically significant difference between
the groups.
CONCLUSIONS— In our review,
six randomized controlled trials could be
included to evaluate the effects of SMBG
in patients with type 2 diabetes who are
not using insulin. The overall effect of
SMBG was a statistically significant de-
crease of 0.39% in HbA1c compared with
the control groups. This is considered
clinically relevant. Based on the U.K. Pro-
spective Diabetes Study, a decrease of
0.39% in HbA1c is expected to reduce risk
of microvascular complications by14%
(3,35,36).
No difference was found between the
SMBG and SMUG groups. Furthermore,
there was little information on other out-
comes, as only one study reported data on
hypoglycemic episodes (32) and only two
studies reported some data on quality of
life and patient satisfaction (29,31).
Table 2—Results of the methodological quality assessment by use of the internal validity criteria of the Maastricht-Amsterdam list (23)
Criteria
Fontbonne
(14)
Allen
(30)
Muchmore
(29)
Schwedes
(31)
Guerci
(32)
Davidson
(33)
Was the method of randomization adequate?      
Was the treatment allocation concealed? ?  ? ? ? ?
Were the groups similar at baseline regarding the most
important prognostic indicators?
     
Was the patient blinded to the intervention? NA NA NA NA NA NA
Was the care provider blinded to the intervention? NA NA NA NA NA NA
Was the outcome assessor blinded to the intervention? ? ? ? ? ? 
Were cointerventions avoided or comparable? ?  ?   
Was the compliance acceptable in both groups?     ? 
Was the withdrawal/drop-out rate described and acceptable?      
Was the timing of the outcome assessment in all groups similar?      
Did the analysis include an intention-to-treat analysis? ?  ?   
Total quality score 5 6 5 5 5 7
NA, not applicable for this type of intervention; , criteria answered with “yes”; , criteria answered with “no”; ?, criteria answered with “don’t know”.
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When assessing the studies individu-
ally, only two studies found a significant
effect of SMBG on HbA1c (31,32). There
are several possible explanations. The two
significant studies (Schwedes et al. [31]
and Guerci et al. [32]) had 113 and 345
patients, respectively, in their interven-
tion groups, whereas the other studies
had 12–68 patients. In addition, the fre-
quency of monitoring blood glucose dif-
fered between the studies, as did diabetes
duration and HbA1c level at baseline. Fur-
thermore, participants in a randomized
controlled trial might be motivated in
both the intervention and control group
to improve their behavior by the knowl-
edge that outcome measures are being ob-
served. This so-called Hawthorne effect
could also have resulted in a underestima-
tion of the efficacy of SMBG (34,37).
A limitation of three studies was that
no standard instructions were given to the
patients to adjust their behavior and
change their lifestyle and medication to
modify their glucose values. Davidson et
al. (33) had the only blinded study, which
guarantees that the education was the
same in the groups. Supervision was pro-
vided in both groups by a dietician and a
nurse who made therapeutic decisions ac-
cording to detailed algorithms while un-
aware of the SMBG status of the patient.
HbA1c levels decreased 0.2% more in the
SMBG group, but the change was not sta-
tistically significant. This might be due to
the small number of patients included in
the study or to the possibility that the
mostly poorly educated minority popula-
tion might not have adequately inter-
preted the information provided by the
nurses. Also, Faas et al. (5) earlier de-
scribed that education on how to change
lifestyle habits is essential to show posi-
tive effects of SMBG on glycemic control.
The control group should receive the
same topics on lifestyle with the same in-
tensity to evaluate the effect of SMBG.
Nonrandomized controlled trials
Because we only found six randomized
controlled trials, we also briefly discuss
nonrandomized controlled trials. We
found seven studies that met all other cri-
teria on the study population, interven-
tion, and outcome measures.
Patrick et al. (38) studied patients
who performed SMBG in a hospital clinic.
Rindone et al. (39) selected medical
records of patients of the previous 2 years
and compared those who did receive a
prescription for SMBG with those who
did not receive a prescription. Both stud-
ies found no differences in the improve-
ment in HbA1c values in patients who did
and did not use SMBG. Gallichan et al.
(40) performed a survey by questionnaire
of current self-monitoring preferences, at-
titudes, and practices of type 2 diabetic
patients on oral hypoglycemic agents. The
group that used urine glucose monitoring
was selected for a 6-month trial, with one
group continuing urine testing and the
other starting SMBG. This study also did
not find differences in fructosamine levels
between groups. Miles et al. (41) com-
pared home testing of blood and urine in
newly diagnosed patients with type 2 di-
abetes in a randomized cross-over trial.
After 3 months of testing, all patients were
crossed-over to the other method of self-
monitoring. The improvements in HbA1c
and quality of life score did not differ be-
tween the groups. Franciosi et al. (42) in-
vestigated the frequency of SMBG and its
association with metabolic control and
quality of life by use of a questionnaire.
No association was found between a
higher frequency of SMBG and a better
glycemic control in patients with type 2
diabetes who are not using insulin. How-
ever, SMBG frequency of at least one time
a day was significantly related to higher
levels of distress, worries, and depressive
symptoms. Distress and worries were also
significantly related to a SMBG frequency
of at least one time per week. Karter et al.
(10) used a cohort design (n 17,601) to
assess the association between SMBG and
glycemic control. They found that moni-
toring at the recommended frequency (at
least daily) was associated with a better
HbA1c level of 0.4% (P 	 0.0001) com-
pared with less frequent monitoring. Be-
cause of the study design, it cannot be
determined if the association between
SMBG and glycemic control was causal,
since we cannot exclude the possibility
that more motivated subjects choose to
Figure 1—Meta-analyses of HbA1c values (measured in percent) of SMBG intervention trials with control groups (A) and SMUG groups (B).
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initiate SMBG. Soumerai et al. (43) eval-
uated a policy providing free blood glu-
cose monitors, and they found that
initiating SMBG was associated with a sig-
nificant reduction in HbA1c levels, al-
though only in patients with a poor
glycemic control at baseline (HbA1c
10%) compared with patients with
good or adequate glycemic control
(HbA1c 	10.0%).
Thus, one of the seven described non-
randomized controlled trials found an im-
provement in HbA1c levels as a result of
monitoring at least daily compared with
less frequent monitoring (10), and one
trial found a significant decrease in HbA1c
levels in the patients with a poor glycemic
control (43). No long-term information
was available on the effects of SMBG, as
most studies had a follow-up of only 6
months. Furthermore, there were very
few data on the effects of SMBG on quality
of life, well-being, patient satisfaction,
and hypoglycemic episodes. Moreover,
the role of education in SMBG could not
be distinguished from the effect of SMBG.
Methodological issues
The conclusion from this review that
SMBG has a beneficial effect on HbA1c in
patients with type 2 diabetes who are not
using insulin should be interpreted with
caution, as the methodological quality of
the trials, as judged by an a priori deter-
mined cutoff on a score list, was limited in
four of the six included studies (23). The
fact that the concealment of treatment al-
location was not clear in all studies is an
important indication for selection bias.
Schulz et al. found that trials with inade-
quate or unclear allocation concealment
yielded exaggerated estimates of treat-
ment effects (19).
In addition, the studies were clini-
cally heterogeneous in their study popu-
lations and interventions. Because there
was no statistical heterogeneity, we could
still perform the meta-analysis; however,
it is possible that some studies have influ-
enced the overall effect. Schwedes et al.
(31) provided education in the SMBG
group only, and the decrease in HbA1c
may have been at least partly due to edu-
cation. The baseline HbA1c values of the
studies were also varying from 12.4% in
Allen et al. to 8.2% in Fontbonne et al.,
which might have influenced the results.
We performed an extensive literature
search in three electronic databases that
are considered to be of high quality; how-
ever, it is possible that we missed some
relevant trials that were not published or
not included in these databases. Further-
more, we did not include any unpub-
lished trials. These issues might have
caused an overestimated effect of SMBG
due to publication bias (44).
Implications for practice and
research
To answer the question if patients with
type 2 diabetes who are not using insulin
might benefit from SMBG, a large ran-
domized controlled trial with a follow-up
period to also investigate long-term ef-
fects should be carried out. It should ful-
fill all the methodological criteria of our
checklist (Table 2). This trial should also
measure quality of life, well-being, patient
satisfaction, and hypoglycaemic episodes
as well as glycemic control. Moreover,
such a trial should also include a stan-
dardized treatment program on diet and
lifestyle in both the intervention and con-
trol groups.
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